Dr. Paul Sugarbaker

World-renowned oncologist, Dr. Paul Sugarbaker, is a specialist in gastrointestinal oncology and currently stands as the Chief of the Peritoneal Surface Malignancy Program and the Director of the Center for Gastrointestinal Malignancies at the Washington Hospital Center in Washington, DC.

Get Your Free Mesothelioma Guide

He has dedicated his career to investigating rare diseases, in particularly peritoneal mesothelioma. Sugarbaker believes that this rare form of cancer can, one day, be cured, and is known as a ‘last hope’ for late-stage peritoneal mesothelioma patients who have been turned down by other surgeons.

About Dr. Sugarbaker

Dr. Paul Sugarbaker is the son of a cancer surgeon, so perhaps it was inevitable that his path should take him into medicine. His older brother, the late Dr. David Sugarbaker, is an internationally recognized thoracic surgeon who specialized in the treatment of mesothelioma.

Dr. Paul Sugarbaker is most notable for pioneering a specialized treatment to cure abdominal cancers, called cytoreductive surgery with HIPEC. The cytoreductive surgery is used with heated intraoperative intraperitoneal chemotherapy (HIPEC)—a treatment approach known as ‘The Sugarbaker Procedure.’ Though the method was widely criticized, it is now a common procedure to treat mesothelioma patients. Survival rates are now rising in conjunction with cancer research.

Over half of peritoneal mesothelioma patients who undergo “The Sugarbaker Procedure”—cytoreduction with HIPEC—live 5 years or longer.

Prior to cytoreduction with HIPEC becoming a standard peritoneal mesothelioma treatment, patients could expect to survive less than 21 months. Dr. Paul Sugarbaker’s treatment approach has dramatically increased survival times and ignited new hope for patients and their families.

As a founding member of the International Society of Regional Cancer Therapy, Dr. Paul Sugarbaker has received the Distinguished Service Award from the American Society of Abdominal Surgeons. His work has also taken him overseas, lecturing at numerous universities and becoming a member of The Royal College of Surgeons of England and the Royal College of Physicians and Surgeons of Glasgow, Scotland.


Dr. Paul Sugarbaker works from the Washington Cancer Institute in Washington Hospital Centre, Washington D.C.

MedStar Washington Hospital Centre

110 Irving St NW

Washington DC 20010



Growing up in Missouri, Dr. Paul Sugarbaker moved to New York City to attend medical school at Cornell University Medical College before progressing to his residency at the Peter Bent Brigham Hospital (now known as Brigham and Women’s Hospital) in Boston. In his final year, Dr. Sugarbaker was named Surgical Chief Resident, before going completing his fellowship at Massachusetts General Hospital in Boston.

Dr. Paul Sugarbaker later achieved an MA degree in Immunology from Harvard Graduate School of Arts and Sciences. After his training in surgery at Peter Bent Brigham Hospital, Dr. Sugarbaker spent ten years as a senior surgeon at the National Institute of Health, National Cancer Institute.

Dr. Sugarbaker is a member of the Royal College of Surgeons of England, and the Royal College of Physicians and Surgeons of Glasgow, Scotland. He also occupies the editorial boards of eleven journals and is a member of the American College of Surgeons, European Society of Surgical Oncology and a founding member of the International Society of Regional Cancer Therapy.

In 1989, Dr. Paul Sugarbaker was appointed Director of the Washington Cancer Institute at MedStar Washington Hospital Centre and has been working there for over 20 years. After only three years into the position, he also became Director of the Program in Peritoneal Surface Oncology within the same cancer institute.

Dr. Paul Sugarbaker’s Medical Specializations

Dr. Paul Sugarbaker specializes in rare malignancies and cancers such as mesothelioma and is frequently regarded as a pioneer in the field of cytoreductive surgery. Thanks to his work on advanced-stage abdominal cancers, he coined a new method named ‘The Sugarbaker Procedure.’

The “Sugarbaker Procedure” is a treatment designed for peritoneal mesothelioma and was initially criticised for being too radical. Persevering with the technique he believed in, Dr. Sugarbaker began openly promoting his procedure as the safest way to treat these rare, high-risk cancers.

The surgery itself begins by removing the lining of the abdomen so that the surgeon can thoroughly examine all organs for cancer. At this stage, they meticulously remove the mesothelioma cells before pumping in a heated chemotherapy (HIPEC) solution for up to 90 minutes.

Using the HIPEC method allows the organs to bathe in the substance before rinsing out the solution and closing the incisions. It’s a lengthy procedure, taking up to 10 hours in the worst cases, but it has been credited to lengthen the lives of many patients.

Dr. Paul Sagarker’s motto is:

“It’s what the surgeon doesn’t see that kills the patient.”

It’s Dr. Sugarbaker’s attention to detail that inspires many of his patients to seek his advice and book their treatment. After seeing the success of the procedure, Dr. Sugarbaker and his research have been widely celebrated. His findings have been published in a book on sarcoma surgery, which is available in five languages.

To this date, Dr. Sugarbaker has performed around 1,500 cytoreductive surgeries with heated intraoperative intraperitoneal chemotherapy. His findings have been published in more than 800 books and articles around the world.

Peritoneal Mesothelioma

Dr Sugarbaker’s most notable achievement is his research and investigation into patients with peritoneal mesothelioma. His pioneering ‘Sugarbaker Procedure’ is world renowned, but in recent years he has added long-term regional chemotherapy into the treatment process—a move which has nearly doubled the number of patients expected to reach the five-year survival rate.

Peritoneal mesothelioma starts in the membrane surrounding the abdominal organs and is so rare that less than 1,000 people in the US are diagnosed with it annually. Caused by ingesting or inhaling toxic asbestos fibers, the disease then develops in the abdomen or gastrointestinal system, opposed to the chest and lungs. Common symptoms include abdominal pain, abdominal swelling, weight loss and fluid in the peritoneal cavity, but due to its rarity, it is frequently misdiagnosed as IBS, a hernia or ovarian cancer.

Dr. Paul Sugarbaker’s Work at Washington Hospital Centre

Dr. Sugarbaker has worked at Washington Hospital Centre since 1989 and is currently Chief of the Peritoneal Surface Malignancy Program and the Director of the Center for Gastrointestinal Malignancies. His clinical and investigative research is focused on the treatment of peritoneal (abdominal) cancers.

His 2017 article in the European Journal of Surgical Oncology (EJSO) delved into the results of long-term regional chemotherapy for patients with epithelial (the mesothelioma cell type) peritoneal mesothelioma. His findings show positive results, with the 5-year survival of patients treated with hyperthermic perioperative chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC) and normothermic intraperitoneal chemotherapy (NIPEC) at 75%.

The survival rate for peritoneal mesothelioma is very promising. As research into cancer treatments progresses it suggests that mesothelioma patients may have a cure in the not-so-distant future.

Working with Dr. Paul Sugarbaker

Known as the best surgeon in his field, patients always feel incredibly assured in the capable hands of Dr. Paul Sugarbaker. Being highly detail-oriented, many peritoneal mesothelioma patients seek the help of Dr. Paul Sugarbaker for his expertise, precision, and determination to find a cure.

Dr. Sugarbaker admits that younger patients (and women in particular) have a better chance of seeing positive results after treatment. But he’s adamant that a cure can one day be found to treat everyone. He’s optimistic, yet doesn’t sugar-coat the fact that mesothelioma is a severe disease. Medical oncologists have been cited as saying that mesothelioma could become a manageable disease, like diabetes, but Dr. Sugarbaker doesn’t like the comparison for fear of giving false hope.

For more information on working with Dr. Paul Sugarbaker, please contact the Justice Support Team today.

Author:Stephanie Kidd

Editor-in-Chief of the Mesothelioma Justice Network

Stephanie Kidd

Stephanie Kidd works tirelessly as a dedicated advocate for the vulnerable and underrepresented. Stephanie worked as a copywriter for an agency whose focus was communicating safety procedures on construction work sites. With her extensive background in victim advocacy and a dedication to seeing justice done, Stephanie works hard to ensure that all online content is reliable, truthful and helpful.

Last modified: May 22, 2019

View 5 Sources
  1. Omics Online – Journal, “Paul H Sugarbaker”, Retrieved from: https://www.omicsonline.org/editor-profile/Paul_H_Sugarbaker/. Accessed on January 31, 2018.
  2. MedStar Health
  3. Sugarbaker Oncology, Retrieved from:
    http://www.sugarbakeroncology.com/. Accessed on January 31, 2018.
  4. Journal of Nippon Medical School, “It's what the surgeon doesn't see that kills the patient.” Retrieved from:
    https://www.jstage.jst.go.jp/article/jnms/67/1/67_1_5/_article/-char/en. Accessed on January 31, 2018.
  5. European Journal of Surgical Oncology (EJSO), “Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.” Retrieved fromL https://www.sciencedirect.com/science/article/pii/S0748798317300598. Accessed on January 31, 2018.
Back to Top